Pharmaceutical intermediates are chemical products used in the process of pharmaceutical synthesis, serving as raw materials for the production of APIs. Pharmaceutical intermediates are a crucial component in the chain of pharmaceutical chemical materials, bridging the gap between raw materials and finished pharmaceutical products. They are classified as typical fine chemicals. The company currently focuses on the production of small molecule chemical pharmaceutical intermediates, with a primary emphasis on innovative drug intermediates. The company provides CMO / CDMO services to clients, specifically targeting systemically administered drugs used in the treatment of various conditions such as tumors, mental disorders, cardiovascular diseases, immunological disorders, and antimicrobial applications. The company ' s product development pipeline encompasses over 200 varieties, including pharmaceutical intermediates for targeted therapies in lung cancer, uterine fibroids, and other medical conditions. Strategic partnerships have been established with internationally renowned pharmaceutical companies in these areas.
The company's API production base has been completed and has entered the trial production phase. Multiple product varieties are on the verge of mass production. The company adheres to an international development strategy for its APIs and has synchronized registrations in China, the United States, the European Union, and Japan. Through strategic investments and project development, the company is actively promoting the integration of intermediates and APIs in its CMO / CDMO strategy.